本文關(guān)鍵詞： 呼吸窘迫綜合征 成人 肺纖維化 糖皮質(zhì)激素類　出處：《解放軍醫(yī)學(xué)雜志》2014年09期 　論文類型：期刊論文

【摘要】：目的觀察經(jīng)霧化吸入糖皮質(zhì)激素對成人呼吸窘迫綜合征(ARDS)患者臨床癥狀及肺纖維化的影響。方法選擇2011年12月-2013年6月入住上海市松江區(qū)中心醫(yī)院ICU的ARDS患者53例,隨機分成兩組。A組(常規(guī)治療組)給予常規(guī)治療,B組(霧化治療組)在常規(guī)治療基礎(chǔ)上給予糖皮質(zhì)激素霧化治療(布地奈德,2mg/次,每12h 1次,應(yīng)用12d)。比較兩組氧合指數(shù)、療效及預(yù)后、肺纖維化指標Ⅰ型膠原肽(CoⅠ)、Ⅲ型前膠原肽(PⅢP)及轉(zhuǎn)化生長因子β1(TGF-β1)等的變化,分析常見不良反應(yīng)的發(fā)生率。結(jié)果與A組相比,B組患者第15天氧合指數(shù)明顯改善(P0.05);ELISA法檢測結(jié)果顯示,兩組間CoⅠ、PⅢP、TGF-β1比較差異均有統(tǒng)計學(xué)意義(P0.05);激素治療并未增加不良反應(yīng)的發(fā)生(P0.05)。結(jié)論小劑量霧化吸入糖皮質(zhì)激素可改善ARDS患者氧合指數(shù)及肺纖維化水平,且常見不良反應(yīng)并無增加,提示激素霧化治療ARDS安全有效。
[Abstract]:Objective to observe the effect of inhaled glucocorticoid on ARDS in adult patients with respiratory distress syndrome (RDS). Methods from December 2011 to June 2013, 53 patients with ARDS were admitted to ICU of Songjiang District Central Hospital in Shanghai. Group A was randomly divided into two groups: group A (routine treatment group) and group B (nebulized group) were given glucocorticoid atomization therapy (budesonide 2 mg / time) on the basis of routine treatment. The oxygenation index, curative effect and prognosis of the two groups were compared every 12 hours, and the pulmonary fibrosis index type 鈪，

本文編號：1484860